LAVA Therapeutics
LVTX
LVTX was delisted on the 20th of November, 2025.
13 hedge funds and large institutions have $34.1M invested in LAVA Therapeutics in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 6 closing their positions.
49% more capital invested
Capital invested by funds: $22.8M → $34.1M (+$11.2M)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
1.5% less ownership
Funds ownership: 30.41% → 28.91% (-1.5%)
24% less funds holding
Funds holding: 17 → 13 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$1.68M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$206K |
| 3 |
CC
Cannell Capital
Alta,
Wyoming
|
+$38.3K |
| 4 |
Axa
Paris,
France
|
+$3.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$1.29M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$953K |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$379K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$330K |
| 5 |
Millennium Management
New York
|
-$158K |
LVTX Hedge Fund Activity: Q3 2022 in Review
13 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q3 2022, worth a combined $34.1M — up 49% from $22.8M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of LVTX and 2 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Silverarc Capital Management, opening a new position worth an estimated $1.68M. The largest seller was Nicholas Investment Partners, exiting entirely with an estimated $1.29M sold.
- 13 institutional investors held LAVA Therapeutics (LVTX) as of Q3 2022, down from 17 in Q2 2022.
- Funds reported $34.1M of LAVA Therapeutics stock for Q3 2022, up 49% quarter-over-quarter.
- 2 funds opened new LAVA Therapeutics positions in Q3 2022 and 6 closed out, a net change of -4 holders.
- The largest LAVA Therapeutics buyer in Q3 2022 was Silverarc Capital Management, an estimated $1.68M added.
- The largest LAVA Therapeutics seller in Q3 2022 was Nicholas Investment Partners, an estimated $1.29M sold.
Based on aggregated 13F filings for Q3 2022.